Drug Trial Radar · NCT06017609
Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
314
Actual
Start
Dec 20, 2023
Primary completion
May 18, 2026
Study completion May 18, 2026
Sponsor
- Lead sponsor
- Shionogi Inc.Industry
- Sponsor type
- Industry
- Collaborators
- ICON Clinical Research
- First posted
- Aug 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable, guideline-directed medical therapy for heart failure.
Conditions
- Chronic Heart Failure
Interventions
JTT-861 CapsulesDrug
Active drug capsules containing JTT-861
Placebo CapsulesDrug
Placebo capsules matching in appearance to the active drug capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline to end of treatment (EOT) in left ventricular ejection fraction (LVEF) as assessed by two-dimensional echocardiography (2D-echo)Time frame: 12 Weeks
- Change from baseline to EOT in left ventricular end-systolic volume (LVESV) index as assessed by 2D-echoTime frame: 12 Weeks
- Change from baseline to EOT in left ventricular end-diastolic volume (LVEDV) index as assessed by 2D-echoTime frame: 12 Weeks
- Change from baseline to EOT in left atrial volume (LAV) as assessed by 2D-echoTime frame: 12 Weeks
- Change from baseline to EOT in N-terminal pro b-type natriuretic peptide (NT-pro-BNP) valuesTime frame: 12 Weeks
- Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) scores from baselineTime frame: 16 Weeks
- Number of subjects with treatment-emergent adverse eventsTime frame: Up to 16 Weeks
- Trough plasma concentrations of JTT-861Time frame: Weeks 4, 8 and 12
- Post-dose plasma concentrations of JTT-861Time frame: Weeks 2, 4 and 8
Locations
75 sites in 6 countries. Site status is shown where the registry gives one.
Arensia Exploratory Medicine Inc.
Phoenix, Arizona
Nature Coast Clinical Research
Crystal River, Florida
Indago Research & Health Center, Inc.
Hialeah, Florida
Med Research of Florida
Miami, Florida
Pharma Medical Innovation, Inc.
Miami Lakes, Florida
Floridian Clinical Research
Miami Lakes, Florida
Affinity Health
Park Ridge, Illinois
ASHA Clinical Research-Munster, LLC
Hammond, Indiana
Monroe Research, LLC
West Monroe, Louisiana
Henry Ford Hospital
Detroit, Michigan
Profound Research LLC
Farmington Hills, Michigan
NextStage Clinical Research - (Kansas City [01])
Kansas City, Missouri
Laurelton Heart Specialist P.C.
Rosedale, New York
Capital Area Research, LLC
Camp Hill, Pennsylvania
Onsite Clinical Solutions, LLC
Rock Hill, South Carolina
NextStage Clinical Research-Beaumont- (01)
Beaumont, Texas
Cypress Heart and Vascular Center
Cypress, Texas
NextStage Clinical Research-Port Arthur-(02)
Port Arthur, Texas
Sherman Clinical Research
Sherman, Texas
Waco Cardiology Associates - NextStage Clinical Research
Waco, Texas
Ambulatory for Specialized Outpatient Medical Care in Cardiology Individual Practice- Dr. Elena Dotcheva EOOD
Burgas, Bulgaria
Multiprofile Hospital for Active Treatment "Ivan Skenderov"
Gotse Delchev, Bulgaria
Multiprofile Hospital For Active Treatment Ivan Skenderov EOOD
Gotse Delchev, Bulgaria
University Multiprofile Hospital for Active Treatment Georgi Stranski, EAD
Pleven, Bulgaria
Multiprofile Hospital For Active Treatment Heart and Brain EAD
Pleven, Bulgaria
University Multiprofile Hospital For Active Treatment Saint Georgi EAD
Plovdiv, Bulgaria
Acibadem City Clinic University Multiprofile Hospital For Active Treatment EOOD
Sofia, Bulgaria
Medical Center Hera EOOD
Sofia, Bulgaria
Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD
Sofia, Bulgaria
Diagnostic Consultative Center Convex EOOD
Sofia, Bulgaria
University Multiprofile Hospital for Active Treatment. Sv Anna - Sofia AD
Sofia, Bulgaria
MUDr. Libor Nechvatal s.r.o.
Brno, Czechia
Centrum pro zdraví, s.r.o.
Brno, Czechia
Vojenská nemocnice Brno
Brno, Czechia
Fakultní nemocnice Brno
Brno, Czechia
Edumed s.r.o.
Broumov, Czechia
Edumed s.r.o.
Hradec Králové, Czechia
Edumed s.r.o.
Jaroměř, Czechia
Edumed s.r.o.
Náchod, Czechia
Fakultní nemocnice Ostrava
Ostrava-Poruba, Czechia
Showing 40 of 75 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.